Abstract 310P
Background
Little is known about the underlying biology associated with worse outcomes in Black females with breast cancer (BC) compared to White females. Racial disparities in BC genomic subtypes have been observed with the MammaPrint (MP) risk of distant recurrence and BluePrint (BP) molecular subtyping signatures. To further understand these observations, we compared clinicopathologic features, MP/BP molecular subtype, and survival outcomes by race among females with hormone receptor-positive (HR+), HER2- early stage BC.
Methods
This study included 1,018 participants with HR+HER2- early BC: 509 Black females were matched by age and menopausal status to 509 White females. MP classified tumors as High-Risk or Low-Risk. BP together with MP further classified tumors as Luminal A-Type, Luminal B-Type, or Basal-Type. Recurrence-free survival (RFS) was compared between race and molecular subtype using Kaplan-Meier estimates and log-rank tests. A Cox proportional hazards model was used to analyze the association of MP, BP, race, and clinicopathologic features with survival.
Results
Black females compared to White females had an over-representation of HR+, Basal-Type tumors (11.0% vs 4.8% p<0.001) and worse 3-year RFS (90.1% vs 93.4%; p=0.0066). Basal-Type tumors had worse 3-year RFS (77.9%) compared to Luminal B-Type (91.2%) and Luminal A-Type (96.1%) tumors, independent of race. In a multivariate model controlling for confounders, High Risk Luminal B- and Basal-Type tumors had significantly worse 3-year outcomes compared to Luminal A-Type tumors, independent of race (Luminal B HR=2.87, [1.11-7.40], p=0.029; Basal HR=5.33, [1.56-18.15], p=0.007; Race HR=1.66, [0.87-3.14], p=0.122; LN+ HR=4.51, [2.43-8.37], p<0.001).
Conclusions
MammaPrint and BluePrint classification highlights racial disparities in the distribution of distinct High Risk molecular subtypes among HR+HER2- early BC. However, survival at 3 years was driven by molecular subtype, independent of race, after controlling for potential confounders. These data highlight the importance of tumor genomic testing to inform treatment decisions as we strive to reduce racial survival disparities among Black females with BC.
Clinical trial identification
FLEX Trial: NCT03053193 BEST Study: R01-CA204819.
Editorial acknowledgement
Legal entity responsible for the study
Agendia, Inc.
Funding
Agendia, Inc.
Disclosure
S. Reid: Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Agendia. J. Wei; H. Ramaswamy; N. Stivers; A. Menicucci; W. Audeh: Financial Interests, Personal, Full or part-time Employment: Agendia. All other authors have declared no conflicts of interest.
Resources from the same session
269P - Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
Presenter: Benedetta Pellegrino
Session: Poster session 14
270P - Dissecting molecular heterogeneity of luminal breast cancers using an ion mobility DIA proteomic approach
Presenter: Anne Patsouris
Session: Poster session 14
271P - Overall expression of human endogenous retroviruses in early breast cancer and their correlation with immunogenicity
Presenter: Julie Lecuelle
Session: Poster session 14
272P - Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC
Presenter: Francesca Ligorio
Session: Poster session 14
274P - A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3
Presenter: Giorgi Dzagnidze
Session: Poster session 14
275P - Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer
Presenter: Ting Luo
Session: Poster session 14
276P - SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07
Presenter: Cai Liu
Session: Poster session 14
277P - Long term follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of trastuzumab in patients with HER2-positive breast cancer
Presenter: Jinmei Zhou
Session: Poster session 14
Resources:
Abstract
278P - Prognostic and biologic significance of HER2-low early-stage breast cancer with long-term follow-up
Presenter: Yuka Niwa
Session: Poster session 14
280P - Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making
Presenter: Marta Tapia Céspedes
Session: Poster session 14